Which novel agents are under investigation for the treatment of papillary thyroid carcinoma (PTC)?

Updated: Jun 18, 2020
  • Author: Ponnandai S Somasundar, MD, MPH, FACS; Chief Editor: Neetu Radhakrishnan, MD  more...
  • Print

Novel agents are under active investigation as options for systemic therapy. [58] Agents that have been studied in patients with metastatic thyroid carcinoma includemultitargeted kinase inhibitors (eg, levatinib, sorafenib, sunitinib, axitinib, vandetanib, pazopanib) and BRAF V600E mutation inhibitors (eg, vemurafinib, dabarafenib). [59] Preliminary data suggest that anaplastic lymphoma kinase (ALK) inhibitors such as crizotinib may be useful in PTC with fusion of the striatin (STRN) and the ALK genes. [60]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!